Journal of Thoracic Oncology最新文献

筛选
英文 中文
OA08.03 Datopotamab Deruxtecan Vs Docetaxel in Patients with Non-Small Cell Lung Cancer: Final Overall Survival from TROPION-Lung01 OA08.03 Datopotamab Deruxtecan Vs Docetaxel 在非小细胞肺癌患者中的应用:TROPION-Lung01的最终总生存率
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2024-10-01 DOI: 10.1016/j.jtho.2024.09.048
J. Sands , A. Lisberg , I. Okamoto , L. Paz-Ares , R. Cornelissen , N. Girard , E. Pons-Tostivint , D. Vicente , S. Sugawara , M. Cobo Dols , M. Pérol , C. Mascaux , E. Poddubskaya , S. Kitazono , H. Hayashi , M.H. Hong , E. Felip , R. Hall , O. Juan-Vidal , D. Brungs , M.-J. Ahn
{"title":"OA08.03 Datopotamab Deruxtecan Vs Docetaxel in Patients with Non-Small Cell Lung Cancer: Final Overall Survival from TROPION-Lung01","authors":"J. Sands , A. Lisberg , I. Okamoto , L. Paz-Ares , R. Cornelissen , N. Girard , E. Pons-Tostivint , D. Vicente , S. Sugawara , M. Cobo Dols , M. Pérol , C. Mascaux , E. Poddubskaya , S. Kitazono , H. Hayashi , M.H. Hong , E. Felip , R. Hall , O. Juan-Vidal , D. Brungs , M.-J. Ahn","doi":"10.1016/j.jtho.2024.09.048","DOIUrl":"10.1016/j.jtho.2024.09.048","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"19 10","pages":"Page S24"},"PeriodicalIF":21.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142442893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Response to the Letter to the Editor: “Comment on Stereotactic Body Radiotherapy for Centrally Located Inoperable Early Stage NSCLC: EORTC 22113-08113 LungTech Phase II Trial Results” 致编辑的一封信:"关于立体定向体放射治疗中心位置无法手术的早期 NSCLC:EORTC 22113-08113 LungTech II 期试验结果的评论 "的回复。
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2024-10-01 DOI: 10.1016/j.jtho.2024.08.001
Antonin Levy MD, PhD, Sonja Adebahr MD, Coen Hurkmans PhD, Catherine Fortpied MSs, Cécile Le Pechoux MD, Corinne Faivre-Finn MD, PhD, Ursula Nestle MD, PhD
{"title":"A Response to the Letter to the Editor: “Comment on Stereotactic Body Radiotherapy for Centrally Located Inoperable Early Stage NSCLC: EORTC 22113-08113 LungTech Phase II Trial Results”","authors":"Antonin Levy MD, PhD, Sonja Adebahr MD, Coen Hurkmans PhD, Catherine Fortpied MSs, Cécile Le Pechoux MD, Corinne Faivre-Finn MD, PhD, Ursula Nestle MD, PhD","doi":"10.1016/j.jtho.2024.08.001","DOIUrl":"10.1016/j.jtho.2024.08.001","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"19 10","pages":"Pages e57-e59"},"PeriodicalIF":21.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142381128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MA02.07 AI as Primary Reader in 4-IN-THE-LUNG-RUN Lung Cancer Screening Trial: Impact on Negative Misclassification and Referral Rate MA02.07 AI作为4-IN-THE-LUNG-RUN肺癌筛查试验的主要读者:对阴性错误分类和转诊率的影响
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2024-10-01 DOI: 10.1016/j.jtho.2024.09.103
A. Walstra , H.L. Lancaster , M.A. Heuvelmans , J.W. Gratama , M. Silva , M. Oudkerk
{"title":"MA02.07 AI as Primary Reader in 4-IN-THE-LUNG-RUN Lung Cancer Screening Trial: Impact on Negative Misclassification and Referral Rate","authors":"A. Walstra , H.L. Lancaster , M.A. Heuvelmans , J.W. Gratama , M. Silva , M. Oudkerk","doi":"10.1016/j.jtho.2024.09.103","DOIUrl":"10.1016/j.jtho.2024.09.103","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"19 10","pages":"Page S58"},"PeriodicalIF":21.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142442467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA16.05 Trastuzumab Deruxtecan Monotherapy in Pretreated HER2-overexpressing Nonsquamous Non-Small Cell Lung Cancer: DESTINY-Lung03 Part 1 OA16.05 曲妥珠单抗地罗替康单药治疗预处理HER2-表达的非鳞状非小细胞肺癌:DESTINY-Lung03 第一部分
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2024-10-01 DOI: 10.1016/j.jtho.2024.09.082
D. Planchard , H.R. Kim , T. Suksombooncharoen , R. Li , J. Samol , Y. Runglodvatana , K.-Y. Lee , G.-C. Chang , D. Kowalski , J.-Y. Han , S. Saw , Y. Huang , A. Sookprasert , E. Nakajima , J. Alfon , Y.-T. Chang , J.C.-H. Yang
{"title":"OA16.05 Trastuzumab Deruxtecan Monotherapy in Pretreated HER2-overexpressing Nonsquamous Non-Small Cell Lung Cancer: DESTINY-Lung03 Part 1","authors":"D. Planchard , H.R. Kim , T. Suksombooncharoen , R. Li , J. Samol , Y. Runglodvatana , K.-Y. Lee , G.-C. Chang , D. Kowalski , J.-Y. Han , S. Saw , Y. Huang , A. Sookprasert , E. Nakajima , J. Alfon , Y.-T. Chang , J.C.-H. Yang","doi":"10.1016/j.jtho.2024.09.082","DOIUrl":"10.1016/j.jtho.2024.09.082","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"19 10","pages":"Pages S46-S47"},"PeriodicalIF":21.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142442605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA12.04 Neoadjuvant Concurrent Chemo-Immuno-Radiation Therapy Followed by Surgery for Stage III-N2 NSCLC: SQUAT Trial (WJOG 12119L) OA12.04 III-N2 期 NSCLC 手术后的新辅助化疗-免疫-放疗并行疗法:SQUAT 试验(WJOG 12119L)
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2024-10-01 DOI: 10.1016/j.jtho.2024.09.066
S. Toyooka , A. Hamada , J. Soh , A. Hata , K. Nakamatsu , M. Shimokawa , Y. Yatabe , J. Suzuki , M. Tsuboi , H. Horinouchi , Y. Sakairi , M. Tanahashi , H. Yamamoto , M. Okada , N. Matsuura , H. Shigematsu , Y. Nishimura , N. Yamamoto , K. Nakagawa , T. Mitsudomi
{"title":"OA12.04 Neoadjuvant Concurrent Chemo-Immuno-Radiation Therapy Followed by Surgery for Stage III-N2 NSCLC: SQUAT Trial (WJOG 12119L)","authors":"S. Toyooka , A. Hamada , J. Soh , A. Hata , K. Nakamatsu , M. Shimokawa , Y. Yatabe , J. Suzuki , M. Tsuboi , H. Horinouchi , Y. Sakairi , M. Tanahashi , H. Yamamoto , M. Okada , N. Matsuura , H. Shigematsu , Y. Nishimura , N. Yamamoto , K. Nakagawa , T. Mitsudomi","doi":"10.1016/j.jtho.2024.09.066","DOIUrl":"10.1016/j.jtho.2024.09.066","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"19 10","pages":"Pages S36-S37"},"PeriodicalIF":21.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142442608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA07.04 Optimising Care of Older Patients with Lung Cancer - An Innovative Nurse-led Model of Care OA07.04 优化老年肺癌患者的护理--以护士为主导的创新护理模式
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2024-10-01 DOI: 10.1016/j.jtho.2024.09.045
S. Vinod , N. Knox , K. Knight , V. Bray , A. Khoo , E. Tcharkhedian , J. Campisi , P. Dufton , G. McErlean , M. Agar , L. Hickman
{"title":"OA07.04 Optimising Care of Older Patients with Lung Cancer - An Innovative Nurse-led Model of Care","authors":"S. Vinod , N. Knox , K. Knight , V. Bray , A. Khoo , E. Tcharkhedian , J. Campisi , P. Dufton , G. McErlean , M. Agar , L. Hickman","doi":"10.1016/j.jtho.2024.09.045","DOIUrl":"10.1016/j.jtho.2024.09.045","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"19 10","pages":"Page S22"},"PeriodicalIF":21.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142442670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA13.04 ALINA Safety Results: Adjuvant Alectinib vs Chemotherapy in Patients with Resected ALK+ Non-Small Cell Lung Cancer (NSCLC) OA13.04 ALINA安全性结果:ALK+非小细胞肺癌 (NSCLC) 患者辅助治疗 Alectinib 与化疗的比较
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2024-10-01 DOI: 10.1016/j.jtho.2024.09.070
H. Horinouchi , B.J. Solomon , Y.-L. Wu , F. Barlesi , M. Nishio , J.S. Ahn , D.H. Lee , J.-S. Lee , W. Zhong , M. Hochmair , I. Bondarenko , D. Planchard , A. Rittmeyer , B. Ding , T. Ruf , L. Adler , A. Scalori , R. Dziadziuszko
{"title":"OA13.04 ALINA Safety Results: Adjuvant Alectinib vs Chemotherapy in Patients with Resected ALK+ Non-Small Cell Lung Cancer (NSCLC)","authors":"H. Horinouchi , B.J. Solomon , Y.-L. Wu , F. Barlesi , M. Nishio , J.S. Ahn , D.H. Lee , J.-S. Lee , W. Zhong , M. Hochmair , I. Bondarenko , D. Planchard , A. Rittmeyer , B. Ding , T. Ruf , L. Adler , A. Scalori , R. Dziadziuszko","doi":"10.1016/j.jtho.2024.09.070","DOIUrl":"10.1016/j.jtho.2024.09.070","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"19 10","pages":"Page S39"},"PeriodicalIF":21.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142442691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC 循环肿瘤DNA分析可预测无法切除的III期非小细胞肺癌短程巩固免疫疗法的疗效
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2024-10-01 DOI: 10.1016/j.jtho.2024.06.024
{"title":"Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC","authors":"","doi":"10.1016/j.jtho.2024.06.024","DOIUrl":"10.1016/j.jtho.2024.06.024","url":null,"abstract":"<div><h3>Introduction</h3><div>The current standard of care for patients with inoperable stage III non-small cell lung cancer includes chemoradiotherapy (CRT) followed by 1 year of checkpoint inhibitor (CPI) therapy. Nevertheless, the optimal duration of consolidation CPI remains unknown. Here, we characterized the relationship between circulating tumor DNA (ctDNA) minimal residual disease (MRD) and clinical outcomes of patients with unresectable locally advanced non-small cell lung cancer treated on a phase 2 trial of short-course consolidation immunotherapy after CRT, with the goal of testing whether ctDNA may be able to identify patients who do not require a full year of treatment.</div></div><div><h3>Methods</h3><div>Plasma samples for ctDNA analysis were collected from patients on the Big Ten Cancer Research Consortium LUN 16-081 trial after completion of CRT, before day 1 of cycle 2 (C2D1) of CPI (i.e., 1 mo after treatment start), and at the end of up to 6 months of treatment. Tumor-informed ctDNA MRD analysis was performed using cancer personalized profiling by deep sequencing. Levels of ctDNA at each time point were correlated with clinical outcomes.</div></div><div><h3>Results</h3><div>Detection of ctDNA predicted significantly inferior progression-free survival after completion of CRT (24-mo 29% versus 65%, <em>p</em> = 0.0048), before C2D1 of CPI (24-mo 0% versus 72%, <em>p</em> &lt; 0.0001) and at the end of CPI (24-mo 15% versus 67%, <em>p</em> = 0.0011). In addition, patients with decreasing or undetectable ctDNA levels after 1 cycle of CPI had improved outcomes compared with patients with increasing ctDNA levels (24-mo progression-free survival 72% versus 0%, <em>p</em> &lt; 0.0001). Progression of disease occurred within less than 12 months of starting CPI in all patients with increasing ctDNA levels at C2D1.</div></div><div><h3>Conclusions</h3><div>Detection of ctDNA before, during, or after 6 months of consolidation CPI is strongly associated with inferior outcomes. Our findings suggest that analysis of ctDNA MRD may enable personalizing the duration of consolidation immunotherapy treatment.</div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"19 10","pages":"Pages 1427-1437"},"PeriodicalIF":21.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141544985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA09.03 Randomized, Open-Label, Phase III Study of SAF-189s Versus Crizotinib in First-Line ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) OA09.03 SAF-189s 与克唑替尼(Crizotinib)治疗一线 ALK 阳性晚期非小细胞肺癌 (NSCLC) 的随机、开放标签 III 期研究
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2024-10-01 DOI: 10.1016/j.jtho.2024.09.053
A. Xiong , N. Yang , X. Dong , Y. Fan , L. Xu , P. Pan , Y. Yu , J. Zhou , Y. Li , J. Cui , M. Wang , Y. Zhang , R. Chen , H. Niu , H. Qin , S. Guo , D. Huang , H. Wu , W. Yao , Z. Zhang , C. Zhou
{"title":"OA09.03 Randomized, Open-Label, Phase III Study of SAF-189s Versus Crizotinib in First-Line ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)","authors":"A. Xiong ,&nbsp;N. Yang ,&nbsp;X. Dong ,&nbsp;Y. Fan ,&nbsp;L. Xu ,&nbsp;P. Pan ,&nbsp;Y. Yu ,&nbsp;J. Zhou ,&nbsp;Y. Li ,&nbsp;J. Cui ,&nbsp;M. Wang ,&nbsp;Y. Zhang ,&nbsp;R. Chen ,&nbsp;H. Niu ,&nbsp;H. Qin ,&nbsp;S. Guo ,&nbsp;D. Huang ,&nbsp;H. Wu ,&nbsp;W. Yao ,&nbsp;Z. Zhang ,&nbsp;C. Zhou","doi":"10.1016/j.jtho.2024.09.053","DOIUrl":"10.1016/j.jtho.2024.09.053","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"19 10","pages":"Pages S27-S28"},"PeriodicalIF":21.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142442789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA18.05 Neoadjuvant Versus Adjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial OA18.05 局部晚期食管鳞状细胞癌的新辅助治疗与辅助治疗:随机临床试验
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2024-10-01 DOI: 10.1016/j.jtho.2024.09.089
Y. Zhu , X. Sun , L. Wu , Q. Chen , Q. Wei , P. Ye , S. Han , X. Yu , J. Liu , Q. Zhao , Y. Jiang , X. Zhou , W. Zhang , W. Mao , Y. Xu
{"title":"OA18.05 Neoadjuvant Versus Adjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial","authors":"Y. Zhu ,&nbsp;X. Sun ,&nbsp;L. Wu ,&nbsp;Q. Chen ,&nbsp;Q. Wei ,&nbsp;P. Ye ,&nbsp;S. Han ,&nbsp;X. Yu ,&nbsp;J. Liu ,&nbsp;Q. Zhao ,&nbsp;Y. Jiang ,&nbsp;X. Zhou ,&nbsp;W. Zhang ,&nbsp;W. Mao ,&nbsp;Y. Xu","doi":"10.1016/j.jtho.2024.09.089","DOIUrl":"10.1016/j.jtho.2024.09.089","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"19 10","pages":"Page S51"},"PeriodicalIF":21.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142441046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信